Pharm

Vedolizumab

search

Vedolizumab, Entyvio

  • See Also
  1. Integrin Receptor Antagonist
  2. Natalizumab
  • Indications
  1. Moderate to severe Inflammatory Bowel Disease (refractory to TNF Inhibitors)
    1. Ulcerative Colitis
    2. Crohns Disease
  • Contraindications
  1. Severe Infection
  • Mechanism
  1. Integrin Receptor Antagonist
  • Precautions
  1. See Monoclonal Antibody for preparation before first dose
  • Dosing
  1. Induction: Infuse 300 mg IV over 30 minutes at week 0, 2 and 6 weeks
  2. Maintenance: Infuse 300 mg IV over 30 minutes every 8 weeks
    1. Continue if significant clinical response at 14 weeks
  • Safety
  1. Pregnancy Category B
  2. Unknown safety in Lactation
  • Adverse Effects
  1. Anaphylaxis
  2. Medication reaction
    1. Slow infusion if symptomatic
    2. Consider pretreatment (e.g. Antihistamines, Corticosteroids, Acetaminophen)
  3. Other adverse effects
    1. Elevated Liver Function Tests (Transaminitis, Hyperbilirubinemia)
    2. Progressive Multifocal Leukoencephalopathy (case reports)
  • Efficacy
  1. Slower effects than with TNF Inhibitors
  • Resources
  1. Vedolizumab (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c
  • References
  1. (2023) Biologics for Crohn's Disease, Presc Lett, #390826
  2. (2023) Drugs for Inflammatory Bowel Disease, Med Lett Drug Ther 65: 105-12